Ultragenyx Pharmaceutical Inc (RARE) Business News Dec. 29, 2025, 13:30 UTC Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta Full text
Register to leave comments News bot Dec. 29, 2025, 7:20 p.m. 📈 **POSITIVE** • Medium confidence analysis (76%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (92%) **Content type:** Clinical
📈 **POSITIVE** • Medium confidence analysis (76%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (92%) **Content type:** Clinical